CONNECTING AI & BT

PHARMACEUTICAL RESEARCH AND DEVELOPMENT FOR AGING-RELATED DISEASE

Our mission is to accelerate drug discovery and development by converging our ReBADD new artificial intelligence technology and anti-aging drug HTS technology. We will provide AI solution and aging therapeutics with constant innovation.

About us

Development of anti-aging treatment by removing senescent cells based on artificial intelligence

Due to the lack of molecular and biological mechanisms, anti-aging has been difficult to study. Recently, however, the mechanism by which senolysis can control senescent cells opens an entirely new era of anti-aging therapeutics.

We established the company to utilize research and technology related to the efficient control of senescent cells for the development of anti-aging treatments. Under the strategy that artificial intelligence (AI) technology is essential to create a new concept of drugs that has not existed, experts in the field of Biotechnology (BT) and AI founded the company. Major goal of company is to present a new paradigm for anti-aging drug development.

Currently, we (1) establish cell and animal models that can verify anti-aging target discovery technology, (2) use discovery platforms using artificial intelligence and semi high-throughput drug screening, and (3) develop anti-aging gene therapy. Through these technologies, the aim of company is to become a technology leader in the anti-aging industry by preventing or treating aging-related diseases, prolonging lifespan, and improving the quality of life for the elderly.

 

Main Strategy

그림11.png
• New drugs discovery with maximum binding power and chemical properties for target proteins
• Securing active substances based on high-efficiency drug candidate screening technology
• Verification of leading substance effects in cell and animal models
 

Team

Byung Ju Kim

CEO

Professional Experience: Director, Macrogen, Inc./Senior researcher, DGIST./Research staff member, SAIT, Inc./Associate, Albert Einstein College of Medicine

Education: PhD in Biochemistry, The University of Ottawa Medical School

Sung Jin Ryu

CTO

Professional Experience: Part leader, Samsung bioepis, Inc./Research staff member SAIT, Inc./Visiting fellow, NCI.

Education: PhD in Biochemistry, Seoul National University College of Medicine

그림20.jpg
그림19.png

ADVISORY BOARD

그림13.png

Sang Hyun Park

Advisor

Current: Professor, Yonsei University

Education: PhD in Computer Science, UCLA

그림16.jpg

Chi Hyun Park

Advisor

Current: Assistant Professor, Kangwon National University

Education: PhD in Computer Science, Yonsei University

그림17.jpg

Young-Sam Lee

Advisor

Current: Associate Professor, DGIST

Education: PhD in Cell & Molecular Biology, The University of Texas at Austin

 

History

• 2021. 04. 01 Patent Registration (registration no. 10-2237189)
                                - Machine Learning based Protein-Ligand Binding Predictive Generation Apparatus for Drug Effect Estimation and Operation Method 
• 2021. 03. 24 Certification of Venture Company by KIBO
• 2021. 02. 16 Certification of R&D Center
• 2020. 12. 01 Received Grants of TIPS Program
• 2020. 07. 07 Established UBL Bio Corporation
 

Contact

E.mail: ublbio2020@gmail.com | Tel: 070-4647-3585 | Fax: 050-4207-8294 

경기도 수원시 영통구 영통로 237, 401호 (신동, 에이스 하이엔드타워)

(237 Yeongtong-ro, Room 401, Yeongtong-gu, Suwon-si, 16679 South Korea)

  • Black Facebook Icon
  • Black Twitter Icon
  • Black YouTube Icon

Thanks for submitting!